Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 277

Results For "IMI"

4532 News Found

Hyderabad startup’s Physiotherapy monitoring device ‘Pheezee’ receives USFDA
Medical Device | May 05, 2023

Hyderabad startup’s Physiotherapy monitoring device ‘Pheezee’ receives USFDA

Pheezee is designed to assess musculoskeletal and neuromuscular health.


Strides and Orbicular enter into a strategic partnership to develop a range of nasal sprays
News | May 04, 2023

Strides and Orbicular enter into a strategic partnership to develop a range of nasal sprays

The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m


AstraZeneca Pharma India receives permission for sale and distribution of Trastuzumab deruxtecan
News | May 04, 2023

AstraZeneca Pharma India receives permission for sale and distribution of Trastuzumab deruxtecan

The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India


USFDA puts on hold Sun Pharma trials on dermatological drug
Drug Approval | May 04, 2023

USFDA puts on hold Sun Pharma trials on dermatological drug

Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose


Astec LifeSciences appoints K. Suryanarayan as Chief Financial Officer
People | May 04, 2023

Astec LifeSciences appoints K. Suryanarayan as Chief Financial Officer

He has over two decades of leadership experience as an innovative strategic planner in finance diligence


Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
News | May 03, 2023

Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr

The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year


USFDA Advisory Committee votes  n Lynparza plus Abiraterone and Prednisone  for prostate cancer
Drug Approval | May 03, 2023

USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer

The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients


Lilly's Lebrikizumab shows improved face or hand dermatitis
Clinical Trials | May 02, 2023

Lilly's Lebrikizumab shows improved face or hand dermatitis

Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients


Aptar Digital Health and Healint collaborate for Central Nervous System
Digitisation | May 01, 2023

Aptar Digital Health and Healint collaborate for Central Nervous System

The partnership will capitalize on the combined capabilities of the two organizations


Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
News | April 30, 2023

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23